|
|
||||||||
1 Department of Pediatrics, 2 Department of Cardiothoracic Surgery, and 3 Cardiovascular Research Institute, University of California, San Francisco, California 94143-0106; 4 Department of Pediatrics, New York University, New York, New York 10016; and 5 Department of Pediatrics, Northwestern University Medical School, Chicago, Illinois 60611
| |
ABSTRACT |
|---|
|
|
|---|
Acute partial compression of the fetal ductus arteriosus (DA) results in an initial increase in pulmonary blood flow (PBF) that is followed by acute vasoconstriction. The objective of the present study was to determine the role of nitric oxide (NO)-endothelin-1 (ET-1) interactions in the acute changes in pulmonary vascular tone after in utero partial constriction of the DA. Twelve late-gestation fetal lambs (132-140 days) were instrumented to measure vascular pressures and left PBF. After a 24-h recovery period, acute constriction of the DA was performed by partially inflating a vascular occluder, and the hemodynamic variables were observed for 4 h. In control lambs (n = 7), acute ductal constriction initially increased PBF by 627% (P < 0.05). However, this was followed by active vasoconstriction, such that PBF was restored to preconstriction values by 4 h. This was associated with a 43% decrease in total NO synthase (NOS) activity (P < 0.05) and a 106% increase in plasma ET-1 levels (P < 0.05). Western blot analysis demonstrated no changes in lung tissue endothelial NOS, preproET-1, endothelin-converting enzyme-1, or ETB receptor protein levels. The infusion of PD-156707 (an ETA receptor antagonist, n = 5) completely blocked the vasoconstriction and preserved NOS activity. These data suggest that the fetal pulmonary vasoconstriction after acute constriction of the DA is mediated by NO-ET-1 interactions. These include an increase in ETA receptor-mediated vasoconstriction and an ETA receptor-mediated decrease in NOS activity. The mechanisms of these NO-ET-1 interactions, and their role in mediating acute changes in PBF, warrant further studies.
ductus arteriosus; pulmonary circulation
| |
INTRODUCTION |
|---|
|
|
|---|
INCREASES in fetal pulmonary arterial pressure induced by mechanical constriction of the ductus arteriosus induce an acute increase in pulmonary blood flow that is followed by active vasoconstriction (1). This so-called "myogenic response," which returns pulmonary blood flow to preconstriction values within 2-4 h, may represent an adaptive response of the fetal pulmonary vasculature to maintain the normal low flow (44). However, chronic ductal constriction results in pulmonary vascular remodeling and many of the pathophysiological features of persistent pulmonary hypertension of the newborn (3, 29, 49). In fact, fetal ductal constriction secondary to maternal indomethacin use has been associated with persistent pulmonary hypertension of the newborn (45).
Previous studies have demonstrated that vasoactive factors produced by the vascular endothelium, such as nitric oxide (NO) and endothelin-1 (ET-1), are important mediators of the fetal and transitional pulmonary circulations (11). NO is produced from its precursor, L-arginine, after the activation of endothelial NO synthase (eNOS) (31). Once released, NO diffuses into the smooth muscle cell and generates cGMP (the second messenger of NO-mediated relaxation) after the activation of soluble guanylate cyclase (18). ET-1 is produced from a 203-amino acid peptide precursor (preproET-1), which is then cleaved to form proendothelin-1 (Big ET-1) (51). Big ET-1 is then cleaved by the metalloprotease endothelin-converting enzyme-1 (ECE-1) into its functional form (46). The complex pulmonary vasoactive effects of ET-1, which may include either pulmonary vasoconstriction and/or pulmonary vasodilation, are mediated by at least two different receptors: ETA and ETB. ETA receptors, which are located on vascular smooth muscle cells, mediate vasoconstriction, whereas ETB receptors, which are located on vascular endothelial cells, mediate vasodilation (4, 37).
Evidence that the pulmonary vascular endothelium regulates vascular tone has led to the hypothesis that aberrations in endothelial function participate in the pathophysiology of pulmonary hypertensive disorders. For example, chronic ductal constriction is associated with decreased NO activity and increased ET-1-mediated vasoconstriction (5, 23, 39, 47). In addition, Abman and colleagues (21, 43) have recently demonstrated that acute ductal constriction impairs endothelium-dependent relaxation and that ET blockade attenuates the subsequent decrease in pulmonary blood flow. These data suggest a role for both NO and ET-1 in the acute myogenic response after acute ductal constriction. Increasing data also suggest that endogenous NO and ET-1 participate in the regulation of each other through an autocrine feedback loop. For example, ET-1 stimulates eNOS activity via ETB receptor activation, whereas NO-cGMP production increases ETA receptors in vascular smooth muscle cells and inhibits ET-1 secretion and gene expression in vascular endothelial cells (6, 24, 33). In addition, we have recently demonstrated in the postnatal pulmonary circulation that exogenous NO increases ET-1 release and decreases NOS activity via an ETA receptor-dependent mechanism (26, 48). The potential role of these NO-ET-1 interactions in mediating the acute changes in fetal pulmonary blood flow has not been investigated.
The objective of this study was to determine the role of NO-ET-1 interactions in the dynamic changes in fetal pulmonary blood flow after acute mechanical constriction of the ductus arteriosus. To determine potential alterations in NO and ET-1 after acute ductal constriction, we determined lung tissue NOS activity, plasma ET-1 levels, and lung tissue protein levels of eNOS, preproET-1, ECE-1, and ETB receptors before and 4 h after ductal constriction in the late-gestation fetal lamb. To determine potential NO-ET-1 interactions after ductal constriction, these alterations were compared in an additional group of fetal lambs that were pretreated with the ETA receptor antagonist PD-156707. Lastly, to isolate potential changes related to the experimental protocol, we determined potential alterations in additional fetal lambs without ductal constriction.
| |
METHODS |
|---|
|
|
|---|
Surgical preparation.
Seventeen mixed-breed Western pregnant ewes (132-140 days
gestation, term = 145 days) were operated on under sterile
conditions with the use of local (2% lidocaine hydrochloride) and
intravenous anesthesia (0.002 mg · kg
1 · min
1 diazepam
and 0.3 mg · kg
1 · min
1
ketamine hydrochloride). Fetal anesthesia consisted of local anesthesia
with 2% lidocaine hydrochloride and 15 mg/kg ketamine hydrochloride
intramuscularly. Through a uterine incision, the fetal forelimb was
exposed. Polyvinyl catheters were inserted into the fetal pedal artery
and vein and were advanced to the aorta and inferior vena cava,
respectively. A left lateral thoracotomy was performed in the fourth
intercostal space. The pericardium was incised along the main pulmonary
trunk. Teflon cannulas attached to polyvinyl catheters were inserted
into the proximal main pulmonary trunk, left pulmonary artery, and left
atrium. An ultrasonic flow transducer (Transonic Systems; Ithaca, NY)
was placed around the left pulmonary artery. The ductus arteriosus was
dissected free and infiltrated with 10% formalin to prevent ductal
constriction during manipulation. A vascular occluder was then placed
around the ductus arteriosus but left deflated. A side-biting vascular clamp was utilized to isolate peripheral lung tissue from the right
upper lobe, and the incision was cauterized. Approximately 300 mg of
peripheral lung were obtained for the biopsy to determine NOS activity
and protein levels of eNOS, preproET-1, ECE-1, and ETB
receptor. The thoracotomy incision was then closed in layers. Warm
saline was instilled to replace the lost amniotic fluid, and the
uterine incision was closed. A polyvinyl catheter was placed in the
amniotic cavity. The catheters were filled with heparin sodium,
plugged, and brought to the skin along with the transducer cables,
where they were protected in a pouch secured to the ewe's flank. After
recovery from anesthesia, the ewe was returned to the cage. Antibiotics
(1 million units of penicillin G procaine and 100 mg of gentamicin
sulfate) were administered intravenously to the ewe and into the
amniotic cavity during surgery and daily thereafter. Buprenorphine
(0.01 mg/kg im) was administered for postoperative analgesia. All
protocols were approved by the Committee of Animal Research at the
University of California, San Francisco.
Experimental protocol.
After a 24-h recovery period, the ewe was placed in a study cart with
free access to food and water. The fetal catheters were connected to
transducers, and 60 min were allowed for stabilization. An infusion of
normal saline (n = 12, vehicle control) or PD-156707 (n = 5, a selective ETA receptor
antagonist, 1.0 mg · kg
1 · h
1) was then
begun into the left pulmonary artery and continued throughout the study
period. The dose of PD-156707 was chosen after several previous studies
(19, 26, 32, 34, 35) showed that a 30-min infusion
completely blocked the vasoconstricting effects of exogenous ET-1 and
resulted in steady-state plasma concentrations that blocked
ETA receptors in vivo. Thirty minutes after initiation of
the infusion, baseline measurements of the hemodynamic variables
(pulmonary and systemic arterial pressure, left pulmonary blood flow,
left atrial pressure, and amniotic cavity pressure), systemic arterial
blood gases, and pH were measured (preconstriction). Blood was
collected from the femoral artery for plasma ET-1 determinations.
Measurements.
Pressures were measured by Statham P23Db pressure transducers (Statham
Instruments). Mean pressures were obtained by electrical integration.
All pressures obtained in utero were zeroed against the amniotic cavity
pressure. Left pulmonary blood flow was measured on an ultrasonic
flowmeter (Transonic Systems). All hemodynamic variables were
continuously recorded on a Gould multichannel electrostatic recorder
(Gould; Cleveland, OH). Systemic arterial blood gases and pH were
measured on a Corning 158 pH/blood gas analyzer (Corning Medical and
Scientific; Medfield, MA). Pulmonary vascular resistance was calculated
as follows: (mean pulmonary arterial pressure
left atrial
pressure)/(left pulmonary blood flow/kg fetal weight). The fetal weight
before beginning the infusions was estimated using standardized fetal
sheep growth charts established in our laboratory.
Plasma ET-1 determinations.
Three milliliters of systemic arterial blood were collected and placed
in iced polypropylene tubes containing 150 µl aprotinin and 100 µl
EDTA. The tubes were immediately centrifuged at 4,000 g for
20 min. Collected plasma was treated with equal volumes of 0.1%
trifluoroacetic acid and stored at
70°C. The acidified supernatant
was centrifuged at 1,000 g for 20 min and loaded on a 3 × 18 C18 Sep-Pak column (Peninsula Laboratories; Belmont, CA)
equilibrated with 0.1% trifluoroacetic acid. The adsorbed material was eluted with 3 ml of 0.1% trifluoroacetic acid-60% acetronitrile. The eluant was dried in a Savant speed vac and stored at
70°C or assayed immediately for immunoreactive ET-1. ET-1 standard,
125I-labeled ET-1 ([125I]ET-1), anti-ET
antibody, and secondary antibody were purchased from Peninsula
Laboratories. Cross-reactivity for measured human and bovine ET-1
antiserum is 100% for human ET-1, 7% for human ET-2 and ET-3, and 0%
for bovine ET-2 and ET-3. Inter- and intra-assay variabilities
were 10% and 4%, respectively. Each sample was assayed in duplicate
(26).
Assay for NOS activity.
This was performed using the conversion of [3H]arginine
to [3H]citrulline as a measure of NOS activity
essentially as described by Bush et al. (7). Briefly, lung
tissues were homogenized in NOS assay buffer [50 mM Tris · HCl
(pH 7.5) containing 0.1 mM EDTA and 0.1 mM EGTA] with a protease
inhibitor cocktail. Enzyme reactions were carried out at 37°C in the
presence of total lung protein extracts (500 µg), 1 mM NADPH, 14 µM
tetrahydrobiopterin, 100 µM FAD, 1 mM MgCl2, 5 µM
unlabeled L-arginine, 15 nM
[3H]arginine, 25 units calmodulin, and 5 mM
calcium to produce conditions that drive the reaction at maximal
velocity. Duplicate assays were run in the presence of the NOS
inhibitor N
-nitro-L-arginine
methyl ester (L-NAME). Assays were
incubated for 30 min such that no more than 20% of the
[3H]arginine was metabolized to insure that the substrate
was not limiting. The reactions were stopped by the addition of iced
stop buffer [20 mM sodium acetate (pH 5), 1 mM
L-citrulline, 2 mM EDTA, and 0.2 mM EGTA] and then applied
to columns containing 1 ml of Dowex AG50W-X8 resin, Na+
form, preequilibrated with 1 N NaOH. [3H]citrulline was
then quantitated by scintillation counting.
Preparation of protein extracts and Western blot analysis.
Lung protein extracts were prepared by homogenizing peripheral lung
tissues in Triton lysis buffer [50 mM Tris · HCl (pH 7.6), 0.5% Triton X-100, and 20% glycerol] containing a protease inhibitor cocktail. Extracts were then clarified by centrifugation (15,000 g × 10 min at 4°C). Supernatant fractions were then
assayed for protein concentration using the Bradford reagent (Bio-Rad;
Richmond, CA) and used for Western blot analysis. Western blot analysis was performed as previously described (5, 26). Briefly,
protein extracts (25 µg) were separated on 7.5% denaturing
polyacrylamide gels for eNOS and ECE-1
, 10% denaturing
polyacrylamide gels for ETB receptors, and 4-20%
gradient denaturing polyacrylamide gradient gels for preproET-1. A
positive control was also included for the ECE-1
Western blot. This
consisted of protein extracts (10 µg) prepared from COS-7 cells
transiently transfected with a mammalian expression vector containing
the full-length bovine ECE-1
cDNA (a generous gift from Dr. M. Yanagisawa, Howard Hughes Medical Institute, University of Texas
Southwestern, Dallas, TX). All gels were electrophoretically
transferred to Hybond-polyvinylidene difluoride membranes (Amersham;
Arlington Heights, IL). The membranes were blocked with 5%
nonfat dry milk in Tris-buffered saline (TBS) containing 0.1% Tween.
After being blocked, the membranes were incubated at room temperature
with the appropriate dilution of the antiserum of interest (1:2,500 for
eNOS, 1:1,000 for ECE-1
and ETB receptor, and 1:500 for
preproET-1), washed with TBS containing 0.1% Tween, and then incubated
with a either an anti-mouse IgG-horseradish peroxidase conjugate
(1:1,000 dilution) for eNOS, a goat anti-rabbit IgG-horseradish
peroxidase conjugate for ECE-1
and ETB receptor, or a
goat anti-sheep IgG-horseradish peroxidase conjugate for preproET-1.
After the membranes were washed, chemiluminescence was used to detect
the protein bands.
antisera were generated as previously
described (26). The ETB receptor antiserum was
obtained from Maine Biotechnology Services (Portland, ME). The
eNOS-specific monoclonal antibody was purchased from Transduction
Laboratories (Lexington, KY). The purified ET-1 was purchased from
Sigma (St. Louis, MO).
Positive controls were run to demonstrate antibody specificity. The
methodology and exposure times used were those that we have previously
demonstrated to be within the linear range of the autoradiographic film
and able to detect changes in lung protein expression (5,
26).
Statistical analysis. The means ± SD were calculated for the baseline hemodynamic variables, systemic arterial blood gases, pH, plasma ET-1 concentrations, and tissue NOS activity. The general hemodynamic variables, systemic arterial blood gases, and pH were compared over time within each group by ANOVA for repeated measures followed by Student-Newman-Keuls test for post hoc testing of multiple comparisons as appropriate. For NOS activity, results from preocclusion lungs were assigned a value of 1 (relative activity). Pre- and postductal constriction ET-1 concentrations and NOS activity were compared by the paired t-test. Comparisons between treatment groups (PD-156707 vs. control) were made by ANOVA for repeated measures followed by the unpaired t-test.
Quantitation of autoradiographic results was performed by scanning (Hewlett-Packard SCA Jet IICX, Hewlett-Packard; Palo Alto, CA) the bands of interest into an image-editing software program (Adobe Photoshop, Adobe Systems; Mt. View, CA). Band intensities from Western blot analyses were analyzed densitometrically on a Macintosh computer (model 9500, Apple Computer; Cupertino, CA) using the public domain NIH Image program (developed at NIH and available on the Internet at http://rsb.info.nih.gov/ nih-image). For Western blot analysis, to ensure equal protein loading, duplicate polyacrylamide gels were run. One was stained with Coomassie blue. In the expected molecular weight range of each protein of interest, the density of the Coomassie blue bands was determined and utilized to normalize the Western blot band intensities. Results from preocclusion lungs were assigned a value of 1 (relative protein). The means ± SD were calculated for the relative protein at pre- and postductal constriction. Comparisons were made by the paired t-test. P < 0.05 was considered statistically significant.| |
RESULTS |
|---|
|
|
|---|
There were no differences in gestational age, weight, sex distribution, or baseline hemodynamic variables between control, PD-156707-treated, and nonconstricted fetal lambs (data not shown).
In control lambs, acute ductal constriction rapidly increased mean
pulmonary arterial pressure and left pulmonary blood flow (P < 0.05). Left pulmonary vascular resistance
decreased (P < 0.05). Mean systemic arterial pressure,
left atrial pressure, systemic arterial blood gases, and pH were all
unchanged (Table 1). During the 4-h study
period, pulmonary arterial pressure remained increased, but left
pulmonary blood flow and pulmonary vascular resistance returned to
preconstriction values (Fig. 1). In fact,
compared with 30-min postconstriction, pulmonary blood flow was
decreased after 4 h and pulmonary vascular resistance was
increased (P < 0.05; Fig. 1).
|
|
To determine the effects of ductal constriction on endogenous NO
activity, we determined tissue NOS activity and eNOS protein levels
before and 4 h after ductal constriction. We found that NOS
activity decreased by 43% (P < 0.05; Fig.
2 and Table
2). However, eNOS protein
levels were unchanged (Fig. 3 and Table 2). In the acute open-chest protocol, we found that total NOS activity
was already decreased after 30 min of ductal constriction (
49.0%,
P < 0.05, n = 4).
|
|
|
To determine the effects of ductal constriction on endogenous
ET-1 production, we determined plasma ET-1 concentrations and lung
preproET-1, ECE-1, and ETB receptor protein levels before and 4 h after ductal constriction. We found that plasma ET-1
concentrations were increased by 106% (P < 0.05; Fig.
4). In addition, Western blot analysis
demonstrated no change in preproET-1, ECE-1
, or ETB
receptor protein levels during the study period (Figs.
5-7 and Table 2).
|
|
To determine potential NO-ET-1 interactions after ductal constriction, an additional group of fetal lambs were pretreated with the ETA receptor antagonist PD-156707. The infusion of PD-156707 decreased mean pulmonary arterial pressure (from 57.6 ± 10.1 to 52.0 ± 7.3 mmHg, P < 0.05). Mean systemic arterial pressure, left pulmonary blood flow, left pulmonary vascular resistance, left atrial pressure, systemic arterial blood gases, and pH were unchanged.
In PD-156707-treated lambs, acute ductal constriction rapidly increased
mean pulmonary arterial pressure and left pulmonary blood flow
(P < 0.05). Left pulmonary vascular resistance
decreased (P < 0.05). Mean systemic arterial pressure,
left atrial pressure, systemic arterial blood gases, and pH were all
unchanged (Table 3). During the 4-h study
period, pulmonary arterial pressure remained increased, but left
pulmonary blood flow and pulmonary vascular resistance remained
unchanged (Table 3 and Fig. 8). In fact,
in PD-156707-treated lambs, pulmonary blood flow was significantly increased compared with control lambs, and pulmonary vascular resistance was significantly decreased, after 4 h of ductal constriction (P < 0.05; Fig. 8).
|
|
In PD-156707-treated lambs, tissue NOS activity did not decrease after
ductal constriction but significantly increased by 104%
(P < 0.05; Fig. 2 and Table 2). This was associated
with an increase in eNOS protein levels of 94% (P < 0.05; Fig. 3 and Table 2). Plasma ET-1 concentrations were increased to
values that were similar to control lambs (Fig. 4). Similar to control lambs, protein levels of preproET-1, ECE-1, and ETB
receptors were unchanged after ductal constriction (Figs. 5-7 and
Table 2).
|
|
In fetal lambs without ductal constriction, hemodynamic variables,
systemic arterial blood gases, and pH were unchanged during the 4-h
study period (Table 4). Similar to
the PD-156707-treated lambs, tissue NOS activity (114%) and eNOS
protein levels (107%) increased (P < 0.05;
Table 2 and Figs. 2 and 3). Plasma ET-1 levels (from 22.5 ± 2.1 to 21.2 ± 3.0 pg/ml) were unchanged.
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study, we tested the hypothesis that NO-ET-1 interactions mediate the dynamic changes in pulmonary blood flow after acute partial constriction of the ductus arteriosus in the fetal lamb. As previously demonstrated, we found that acute constriction of the ductus arteriosus induced an initial pulmonary vasodilation that was followed by active pulmonary vasoconstriction, returning pulmonary blood flow to preconstriction values within 2-4 h. Associated with these changes, total lung NOS activity decreased by 43% and plasma ET-1 levels increased by 106%. The infusion of PD-156707, an ETA receptor antagonist, blocked the active vasoconstriction while preserving NOS activity. These data suggest that the active vasoconstriction after ductal constriction is mediated, at least in part, by the ETA receptor. Its effects include an increase in ETA receptor-mediated vasoconstriction and/or an ETA receptor-mediated decrease in NOS activity. The latter represents a novel NO-ET-1 interaction of the fetal pulmonary vasculature with important physiological and clinical implications.
Increasing data suggest that both NO and ET-1 are important mediators
of the normal perinatal circulation. For example, studies (30,
38, 42) have revealed maturational increases in NO-mediated relaxation and eNOS gene expression during the late fetal and early
postnatal period. This maturational increase in NO production parallels
the dramatic decrease in pulmonary vascular resistance that occurs at
birth. In addition, in the late-gestation fetal lamb, an infusion of
the NOS inhibitor
N
-nitro-L-arginine markedly
increases resting tone and attenuates the increase in pulmonary blood
flow associated with ventilation at birth (2, 10, 12).
Conversely, selective ETA receptor blockade produces only
small decreases in resting fetal pulmonary resistance and does not
attenuate the increase in pulmonary blood flow at birth (20,
50). Together, these data suggest a major role for NO in
mediating resting fetal pulmonary vascular tone and the fall in
pulmonary vascular resistance during the transitional pulmonary
circulation and a minor role for basal ET-1-induced vasoconstriction in
maintaining the high fetal pulmonary vascular resistance.
In the present study, acute ductal constriction increased plasma ET-1
concentrations by 106%. Increases in plasma ET-1 concentrations may
result from increases in ET-1 production, ET-1 release, and/or decreased ET-1 clearance. The production of ET-1 begins with the cleavage of the translational product preproET-1 into a nonactive 38-amino acid residue known as Big ET-1. Big ET-1 in then cleaved into
its functional form, ET-1, by the endopeptidase ECE-1
(46). ECE-1 exists in two isoforms, ECE-1
and ECE-1
,
with ECE-1
considered to be the most biologically important
(41). Because many studies have suggested that ET-1
production is regulated at the transcriptional level of preproET-1
and/or ECE-1, we determined potential changes in preproET-1 and
ECE-1
protein levels. We found that both preproET-1 and ECE-1
protein levels were unchanged after acute ductal constriction, suggesting that the increased plasma concentrations are independent of
changes in gene expression. In addition, the ETB receptor
has been implicated in the clearance of ET-1 from the circulation, but
we found no changes in ETB receptor protein levels
(13). Rapid ET-1 release from intracellular secretory
granules has been demonstrated after such stimuli as cytokines and
stretch (25, 28). Therefore, the increase in plasma ET-1
induced by ductal constriction may represent an increase in ET-1
release. However, potential changes in ECE-1 activity, NO-induced
displacement of ET-1 from its receptors, and/or potential changes in
ET-1 clearance represent additional potential mechanisms that were not
completely studied but warrant investigation.
To better determine the potential role of ET-1 during acute
ductal constriction, we pretreated five additional fetal lambs with an
ETA receptor antagonist. To selectively block
ETA receptor activity, we utilized PD-156707, a nonpeptide
ETA receptor antagonist. PD-156707 is highly selective for
the ETA receptor and inhibits the binding of
[125I]ET-1 to cloned human ETA receptor and
ETB receptor with inhibitory constant values of 0.17 and
133.8 nM, respectively (34). In rabbits, PD-156707
infusion rates of 0.03 mg · kg
1 · h
1 completely
blocked the vasoconstricting effects of exogenous ET-1, with
corresponding plasma concentrations that were <0.05 µg/ml
(10
7 M) (19, 35). We also performed several
preliminary studies in lambs that demonstrated that PD-156707 infusion
rates of 1.0 mg · kg
1 · h
1
completely and selectively block the vasoconstricting effects of
exogenous ET-1 (250 ng/kg) and produced stable plasma concentrations of
>500 ng/ml within 30 min of initiating the infusion (32). Therefore, in the present study, we utilized an infusion rate of 1.0 mg · kg
1 · h
1, which was
initiated 30 min before ductal constriction. In PD-156707-treated lambs, we found that ductal constriction resulted in a similar increase
in plasma ET-1 levels as demonstrated in the control lambs. However,
the acute pulmonary vasoconstriction after ductal constriction was
completely blocked, suggesting an important role for the
ETA receptor in mediating this constriction.
A second component that may mediate the pulmonary vasoconstriction after ductal constriction is a decrease in NOS activity. In control lambs, we found that total NOS activity decreased by 43% after 4 h. Because eNOS protein levels were unchanged and the decrease was demonstrated as early as 30 min after ductal constriction in our open-chest protocol, the change in activity is likely independent of changes in gene expression. However, the exact mechanisms for the decrease in NOS activity are currently unclear. Our previous in vitro studies (40, 48) utilizing cells cultured from postnatal lambs suggested that vascular smooth muscle cells produce superoxide via an ETA receptor-dependent mechanism. Superoxide may then decrease NOS activity either directly, via the conversion to hydrogen peroxide, or via the production of peroxynitrite. In the intact postnatal lamb, we recently demonstrated that exogenous NO increases ET-1 secretion and decreases endogenous lung NOS activity via ETA receptor signaling (26, 48). In these studies, the dominant mechanism is the formation of peroxynitrite from the binding of superoxide and NO, which nitrates and irreversibly inhibits eNOS (26, 40, 48). In the present study, we demonstrated that the decrease in lung NOS activity after acute ductal constriction can be preserved by the infusion of PD-156707. Therefore, these data support a similar ETA receptor-dependent decrease in NOS activity in the fetal pulmonary circulation after ductal constriction. However, several other posttranslational modifications of NOS, such as protein kinase C-dependent phosphorylation and translocation of NOS within the cytosol, are also known to quickly decrease NOS activity (17, 27). These and other possible mechanisms are currently speculative and warrant further study.
In nonoccluded lambs, we found that total NOS activity increased. Because this was associated with a similar increase in eNOS protein levels, these data suggest that the experimental protocol, independent of ductal manipulation, upregulates eNOS gene expression. The etiology for this upregulation of NOS is unclear and warrants further studies. Potential etiologies include surgically induced increases in catecholamine and prostanoid production, both of which have been shown to upregulate eNOS in different cellular systems, and the fact that the second biopsy was taken ~36 h later in gestation, during a time when eNOS gene expression is increasing (8, 9, 14, 38). Because the experimental protocol alone increased NOS activity, the decrease in NOS activity after ductal constriction in control lambs would tend to be minimized by the protocol, further accentuating the fact that acute ductal constriction decreases NOS activity. Interestingly, eNOS protein levels were not increased in control lambs but remained increased in PD-156707-treated lambs. Because chronic ductal constriction decreases eNOS gene expression, perhaps an early decrease in gene expression is being offset in control lambs by the increase induced by the surgical preparation (5, 39). In addition, ETA receptor blockade has been demonstrated to preserve eNOS protein content in some systems in which eNOS gene expression is downregulated (36). Although chronic ETA receptor blockade attenuates the progression of pulmonary hypertension induced by ductal constriction, its effects on the decrease in eNOS protein levels in this system have not been investigated (22). Therefore, the mechanisms for these interesting interactions remain speculative and warrant further study.
In summary, we demonstrated that acute ductal constriction induces an acute increase in pulmonary blood flow that is followed by active vasoconstriction. Our data suggest that these changes are mediated, at least in part, by ETA receptor-dependent mechanisms. These include an increase in ETA receptor-mediated vasoconstriction, secondary to increased ET-1 levels, and/or an ETA receptor-mediated decrease in NOS activity. Interestingly, the changes demonstrated acutely after ductal constriction in this study, decreased NOS activity and increased ET-1 levels, are similar to the changes demonstrated after chronic ductal constriction and chronic pulmonary hypertensive disorders. For example, in animal models and humans with pulmonary hypertension, decreases in NOS activity and increases in ET-1 are consistently noted (5, 15, 16, 23, 39, 47). Therefore, these novel NO-ET-1 interactions associated with acute changes in pulmonary blood flow may have important physiological and pathophysiological implications. Additional studies of NO-ET-1 interactions in the normal and abnormal pulmonary circulation, and their mechanisms, are warranted.
| |
ACKNOWLEDGEMENTS |
|---|
This research was supported by National Institutes of Health Grants HL-61284 (to J. R. Fineman), HL-60190 (to S. M. Black), and HD-398110 (to S. M. Black), March of Dimes Grants FY99-421 (to J. R. Fineman) and FY00-98 (to S. M. Black), and American Heart Association, Midwest Affiliate, Grant 0051409Z (to S. M. Black).
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: J. R. Fineman, Medical Center at UC-San Francisco, 505 Parnassus Ave., PO Box 0106, San Francisco, CA 94143-0106 (E-mail: jfineman{at}pedcard.ucsf.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpheart.00417.2001
Received 17 May 2001; accepted in final form 6 November 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abman, SH,
and
Accurso FJ.
Acute effects of partial compression of ductus arteriosus on fetal pulmonary circulation.
Am J Physiol Heart Circ Physiol
257:
H626-H634,
1989.
2.
Abman, SH,
Chatfield BA,
Hall SL,
and
McMurtry IF.
Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth.
Am J Physiol Heart Circ Physiol
259:
H1921-H1927,
1990.
3.
Abman, SH,
Shanley PF,
and
Accurso FJ.
Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs.
J Clin Invest
83:
1849-1859,
1989.
4.
Arai, H,
Hori S,
Aramori I,
Ohkubo H,
and
Nakanishi S.
Cloning and expression of a cDNA encoding an endothelin receptor.
Nature
348:
730-732,
1990.
5.
Black, SM,
Johengen MJ,
and
Soifer SJ.
Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs.
Pediatr Res
44:
821-830,
1998.
6.
Boulanger, C,
and
Luscher TF.
Release of endothelin-1 from the porcine aorta: inhibition by endothelium-derived nitric oxide.
J Clin Invest
85:
587-590,
1990.
7.
Bush, PA,
Gonzalez NE,
and
Ignarro LJ.
Biosynthesis of nitric oxide and citrulline from L-arginine by constitutive nitric oxide synthase present in rabbit corpus cavernosum.
Biochem Biophys Res Commun
186:
308-314,
1992.
8.
Clyman, RI,
Mauray F,
Roman C,
Rudolph AM,
and
Heymann MA.
Circulating prostaglandin E2 concentrations and patent ductus arteriosus in fetal and neonatal lambs.
J Pediatr
97:
455-461,
1980.
9.
Dumont, I,
Hardy P,
Peri KG,
Hou X,
Molotchnikoff S,
Varma DR,
and
Chemtob S.
Regulation of endothelial nitric oxide synthase by PGD2 in the developing choroid.
Am J Physiol Heart Circ Physiol
278:
H60-H66,
2000.
10.
Fineman, JR,
Heymann MA,
and
Soifer SJ.
N
-nitro-L-arginine attenuates endothelium-dependent pulmonary vasodilation in lambs.
Am J Physiol Heart Circ Physiol
260:
H1299-H1306,
1991.
11.
Fineman, JR,
Soifer SJ,
and
Heymann MA.
Regulation of pulmonary vascular tone in the perinatal period.
Annu Rev Physiol
57:
115-134,
1995.
12.
Fineman, JR,
Wong J,
Morin FC, III,
Wild LM,
and
Soifer SJ.
Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs.
J Clin Invest
93:
2675-2683,
1994.
13.
Fukuroda, T,
Fujikawa T,
Ozaki S,
Ishikawa K,
Yano M,
and
Nishikibe M.
Clearance of circulating endothelin-1 by ETB receptors in rats.
Biochem Biophys Res Commun
199:
1461-1465,
1994.
14.
Gauthier, C,
Leblais V,
Kobzik L,
Trochu J,
Khandoudi N,
Bril A,
Balligand JL,
and
Marec H.
The negative inotropic effect of
3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle.
J Clin Invest
102:
1377-1384,
1998.
15.
Giaid, A,
and
Saleh D.
Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.
N Engl J Med
333:
214-221,
1995.
16.
Giaid, A,
Yanagisawa M,
Langleben D,
Michel RP,
Levy R,
Shennib H,
Kimura S,
Masaki T,
Duguid WP,
and
Stewart DJ.
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.
N Engl J Med
328:
1732-1739,
1993.
17.
Hirata, K,
Kuroda R,
Sakoda T,
Katayama M,
Inoue N,
Suematsu M,
and
Kawashima S.
Inhibition of endothelial nitric oxide synthase activity by protein kinase C.
Hypertension
25:
180-185,
1995.
18.
Ignarro, LJ,
Ross G,
and
Tillisch J.
Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.
West J Med
154:
51-62,
1991.
19.
Ignasiak, DP,
McClanahan TB,
Saganek LJ,
Potoczak RE,
Hallak H,
and
Gallagher KP.
Effects of endothelin ETA receptor antagonism with PD 156707 on hemodynamics and renal vascular resistance in rabbits.
Eur J Pharmacol
321:
295-300,
1997.
20.
Ivy, DD,
Kinsella JP,
and
Abman SH.
Physiologic characterization of endothelin A and B receptor activity in the ovine fetal pulmonary circulation.
J Clin Invest
93:
2141-2148,
1994.
21.
Ivy, DD,
Kinsella JP,
and
Abman SH.
Endothelin blockade augments pulmonary vasodilation in the ovine fetus.
J Appl Physiol
81:
2481-2487,
1996.
22.
Ivy, DD,
Parker TA,
Ziegler JW,
Galan HL,
Kinsella JP,
Tuder RM,
and
Abman SH.
Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus.
J Clin Invest
99:
1179-1186,
1997.
23.
Ivy, DD,
Ziegler JW,
Dubus MF,
Fox JJ,
Kinsella JP,
and
Abman SH.
Chronic intrauterine pulmonary hypertension alters endothelin receptor activity in the ovine fetal lung.
Pediatr Res
39:
435-442,
1996.
24.
Luscher, TF,
Yang Z,
Tschudi M,
Von Segesser L,
Stulz P,
Boulanger C,
Siebermann R,
Turnia M,
and
Buhler FR.
Interaction between endothelin 1 and endothelium derived relaxing factor in human arteries and veins.
Circ Res
66:
1088-1094,
1990.
25.
Macarthur, H,
Warner TD,
Wood EG,
Corder R,
and
Vane JR.
Endothelin-1 release from cells in culture is elevated both acutely and chronically by short periods of mechanical stretch.
Biochem Biophys Res Commun
200:
395-400,
1994.
26.
McMullan, DM,
Bekker JM,
Johengen MJ,
Hendricks-Munoz K,
Gerrets R,
Black SM,
and
Fineman JR.
Inhaled nitric oxide-induced rebound pulmonary hypertension: a role for endothelin-1.
Am J Physiol Heart Circ Physiol
280:
H777-H785,
2001.
27.
Michel, T,
Li GK,
and
Busconi L.
Phosphorylation and subcellular translocation of endothelial nitric oxide synthase.
Proc Natl Acad Sci USA
90:
6252-6256,
1993.
28.
Mitsutomi, N,
Akashi C,
Odagiri J,
and
Matsumura Y.
Effects of endogenous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells.
Eur J Pharmacol
364:
65-73,
1999.
29.
Morin, FC, III.
Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb.
Pediatr Res
25:
245-240,
1989.
30.
North, AJ,
Star RA,
Brannon TS,
Ujiie K,
Wells LB,
Lowenstein CJ,
Snyder SH,
and
Shaul PW.
Nitric oxide synthase type I and type III gene expression are developmentally regulated in rat lung.
Am J Physiol Lung Cell Mol Physiol
266:
L635-L641,
1994.
31.
Palmer, RMJ,
Ashton DS,
and
Moncada S.
Vascular endothelial cells synthesize nitric oxide from L-arginine.
Nature
333:
664-666,
1988.
32.
Petrossian, E,
Parry AJ,
Reddy VM,
Akkersdijk GP,
McMullan DM,
Thompson L,
Hendricks-Munoz KD,
Hallak H,
Hanley FL,
and
Fineman JR.
Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow.
J Thorac Cardiovasc Surg
117:
314-323,
1999.
33.
Redmond, EM,
Cahill PA,
Hodges R,
Zhang S,
and
Sitzman JV.
Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells.
J Cell Physiol
166:
469-479,
1996.
34.
Reynolds, EE,
Keiser JA,
Haleen SJ,
Walker DM,
Olszewski B,
Schroeder RL,
Taylor DG,
Hwang O,
Welch KM,
and
Flynn MA.
Pharmacological characterization of PD 156707, an orally active ETA receptor antagonist.
J Pharmacol Exp Ther
273:
1410-1417,
1995.
35.
Rossi, DT,
Hallak H,
and
Bradford L.
Liquid chromatographic assay for a butenolide endothelin antagonist (PD 156707) in plasma.
J Chromatogr B Biomed Appl
677:
299-304,
1996.
36.
Ruschitzka, F,
Quaschning T,
Noll G,
deGottardi A,
Rossier MF,
Enseleit F,
Hurlimann D,
Luscher TF,
and
Shaw SG.
Endothelin 1 type A receptor antagonism prevents vascular dysfunction and hypertension induced by 11
-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Circulation
103:
3129-3135,
2001.
37.
Sakurai, T,
Yanagisawa M,
Takuwa Y,
Miyazaki H,
Kimura S,
Goto K,
and
Masaki T.
Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor.
Nature
348:
732-735,
1990.
38.
Shaul, PW,
Farrar MA,
and
Magness RR.
Pulmonary endothelial nitric oxide production is developmentally regulated in the fetus and newborn.
Am J Physiol Heart Circ Physiol
265:
H1056-H1063,
1993.
39.
Shaul, PW,
Yuhanna IS,
German Z,
Chen Z,
Steinhorn RH,
and
Morin FC, III.
Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension.
Am J Physiol Lung Cell Mol Physiol
272:
L1005-L1012,
1997.
40.
Sheehy, AM,
Burson MA,
and
Black SM.
Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: a role for superoxide.
Am J Physiol Lung Cell Mol Physiol
274:
L833-L841,
1998.
41.
Shimada, K,
Takahashi M,
Ikeda M,
and
Tanzawa K.
Identification and characterization of two isoforms of an endothelin-converting enzyme-1.
FEBS Lett
371:
140-144,
1995.
42.
Steinhorn, RH,
Morin FC, III,
Gugino SF,
Giese EC,
and
Russell JA.
Developmental differences in endothelium-dependent responses in isolated ovine pulmonary arteries and veins.
Am J Physiol Heart Circ Physiol
264:
H2162-H2167,
1993.
43.
Storme, L,
Rairigh RL,
Parker TA,
Kinsella JP,
and
Abman SH.
Acute intrauterine pulmonary hypertension impairs endothelium-dependent vasodilation in the ovine fetus.
Pediatr Res
45:
575-581,
1999.
44.
Storme, L,
Rairigh RL,
Parker TA,
Kinsella JP,
and
Abman SH.
In vivo evidence for a myogenic response in the fetal pulmonary circulation.
Pediatr Res
45:
425-431,
1999.
45.
Turner, GR,
and
Levin DL.
Prostaglandin synthesis inhibition in persistent pulmonary hypertension of the newborn.
Clin Perinatol
11:
581-589,
1984.
46.
Turner, AJ,
and
Murphy LJ.
Molecular pharmacology of endothelin converting enzymes.
Biochem Pharmacol
51:
91-102,
1996.
47.
Villamor, E,
Le Cras TD,
Horan MP,
Halbower AC,
Tuder RM,
and
Abman SH.
Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus.
Am J Physiol Lung Cell Mol Physiol
272:
L1013-L1020,
1997.
48.
Wedgwood, S,
McMullan DM,
Bekker JM,
Fineman JR,
and
Black SM.
A role for ET-1 induced superoxide production in rebound pulmonary hypertension associated with inhaled NO therapy.
Circ Res
89:
357-364,
2001.
49.
Wild, LM,
Nickerson PA,
and
Morin FC, III.
Ligating the ductus arteriosus before birth remodels the pulmonary vasculature of the lamb.
Pediatr Res
25:
251-257,
1989.
50.
Winters, J,
Wong J,
Van Dyke D,
Johengen M,
Heymann MA,
and
Fineman JR.
Endothelin receptor blockade does not alter the increase in pulmonary blood flow due to oxygen ventilation in fetal lambs.
Pediatr Res
40:
152-157,
1996.
51.
Yanagisawa, M,
Kurihara H,
Kimura S,
Tomobe Y,
Kobayashi M,
Mitsui Y,
Yazaki Y,
Goto K,
and
Masaki T.
A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
Nature
332:
411-415,
1988.
This article has been cited by other articles:
![]() |
J. J. Smolich, J. P. Mynard, and D. J. Penny Simultaneous pulmonary trunk and pulmonary arterial wave intensity analysis in fetal lambs: evidence for cyclical, midsystolic pulmonary vasoconstriction Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1554 - R1562. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. H. Leuchte, T. Meis, M. El-Nounou, J. Michalek, and J. Behr Inhalation of endothelin receptor blockers in pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L772 - L777. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Oishi, A. Azakie, C. Harmon, R. K. Fitzgerald, A. Grobe, J. Xu, K. Hendricks-Munoz, S. M. Black, and J. R. Fineman Nitric oxide-endothelin-1 interactions after surgically induced acute increases in pulmonary blood flow in intact lambs Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1922 - H1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. C. Coumans, Y. Garnier, S. Supcun, A. Jensen, T. H. M. Hasaart, and R. Berger The Role of Nitric Oxide on Fetal Cardiovascular Control During Normoxia and Acute Hypoxia in 0.75 Gestation Sheep Reproductive Sciences, July 1, 2003; 10(5): 275 - 282. [Abstract] [PDF] |
||||
![]() |
G. G. Konduri, J. Ou, Y. Shi, and K. A. Pritchard Jr. Decreased association of HSP90 impairs endothelial nitric oxide synthase in fetal lambs with persistent pulmonary hypertension Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H204 - H211. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||